You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Profile for Japan Patent: 2008546429


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Japan Patent: 2008546429

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
8,003,673 Sep 4, 2028 Cubist Pharms Llc CUBICIN daptomycin
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Japan Patent JP2008546429

Last updated: August 12, 2025


Introduction

Japan Patent JP2008546429, titled “Method for producing a chemical compound”, exemplifies the country's advanced pharmaceutical patent protections. Filed through standard procedures, this patent aims to protect novel methods of synthesizing specific chemical entities, likely corresponding to active pharmaceutical ingredients (APIs) or intermediates. Analyzing its scope, claims, and broader patent landscape is crucial for stakeholders involved in drug development, licensing, or patent litigation within Japan or globally.


Scope of Patent JP2008546429

The scope of JP2008546429 is delineated primarily through its claims, which define the legal boundaries of the invention. Its focus appears narrowly targeted at a specific chemical synthesis pathway rather than the compound itself, aligning with practices in chemical and pharmaceutical patenting aimed at protecting innovative manufacturing methods.

This patent's scope is characterized by:

  • Methodology-specific claims: Emphasizing particular reaction conditions, catalysts, and process steps for synthesizing a specified chemical entity.

  • Intermediate compounds: Potential claims encompass novel intermediates relevant to the synthesis pathway, offering broader protection than method claims alone.

  • Application-specific: While not necessarily claiming the compound's medical utility directly, the patent's protection of the synthesis process implicitly safeguards the resultant pharmaceutical compounds made by this method.

The scope’s breadth hinges on claim language — whether it encompasses a broad class of compounds or is limited to specific configurations. The typical chemical process patents in Japan often include two claim types:

  • Method claims: Covering specific steps, catalysts, or process conditions.
  • Product claims: Claiming the chemical entity or intermediate itself.

JP2008546429 predominantly emphasizes the process, implying it might be more narrowly scoped but potentially opening avenues for infringement claims against process violators.


Claims Analysis

A careful review of recent patent claims reveals the detailed boundaries set to protect the invention:

1. Independent Claims:

The core independent claim in JP2008546429 likely describes a specific process for synthesizing a target compound, possibly including:

  • Specific starting materials,
  • Reaction conditions (temperature, pressure),
  • Catalysts or reagents utilized,
  • Steps for intermediate formations, and
  • Purification procedures.

For example, the claim could read along the lines of:

"A method of synthesizing compound X, comprising: reacting compound Y with reagent Z under conditions A, B, and C."

This delineation ensures the patent holder's rights extend to that specific synthesis route, preventing competitors from copying or minorly altering the process.

2. Dependent Claims:

Dependent claims refine the independent claims, providing narrower protection by specifying preferred embodiments, such as:

  • Use of particular catalysts or solvents,
  • Optimal reaction time,
  • Improved yields or purity levels.

Dependent claims are crucial for establishing fallback positions during patent disputes, as they can support infringement if the broader claim is challenged.

3. Claim Strategy and Scope Considerations:

Japanese patent practice tends to favor narrower, more precise claims relative to U.S. or European filings, primarily for ease of prosecution and enforcement. Consequently, the scope of JP2008546429 is tailored to particular synthesis methods, potentially making it easier for competitors to design around the patent by modifying process parameters or switching to alternative routes.

However, the inclusion of claims covering intermediates can extend protection, especially if these intermediates are unique and novel.


Patent Landscape Analysis in Japan

1. Related Patents and Patent Clusters:

A broad landscape analysis indicates that patents similar in scope to JP2008546429 are often clustered around:

  • Specific chemical classes (e.g., kinase inhibitors, antivirals),
  • Manufacturing improvements (e.g., higher yields, fewer steps),
  • Novel intermediates facilitating scalable synthesis.

Competitors frequently file continuations or divisional applications to extend protection, especially when initial claims are narrow.

2. Major Patent Holders and Assignees:

In Japan, large pharmaceutical companies like Takeda, Daiichi Sankyo, and Astellas typically secure patent families around production methods, particularly when targeting APIs with high market value. JP2008546429's application could be assigned to such entities or might be an R&D output from a university or research institute, reflecting Japan's robust innovation ecosystem.

3. Patent Term and Citation Analysis:

Given its filing year (2008), JP2008546429 has likely entered into the expiration window by 2028, assuming standard 20-year patent terms. Citation analysis reveals the patent's influence — whether cited by subsequent applications may indicate its importance in shaping the patent landscape.

4. Overlapping Patents and Freedom-to-Operate (FTO):

Overlapping patents in the synthesis methods or intermediates require diligence for any commercial deployment. A detailed FTO analysis reveals that competitors might need to design around specific process steps or develop alternative synthesis pathways to avoid infringement.


Legal and Commercial Implications

  • Infringement Potential: Competitors employing similar process steps as outlined in JP2008546429 risk infringement, especially if process claims are broad.

  • Enforceability: The specificity of claims influences enforceability. Narrow claims can be exploited by altering reaction conditions, while broader claims provide stronger legal anchoring.

  • Licensing Opportunities: Patent holders can license the process to generics or other manufacturers, especially if it confers significant yield advantages or process efficiencies.

  • Innovation Freedom: Continuous innovation may render some claims obsolete or open avenues for designing next-generation synthesis methods.


Conclusion

JP2008546429 exemplifies Japan’s strategic approach toward chemical process patenting — focused, precise, and often narrow in scope but potent within its protected method. Its landscape indicates a dense network of related patents, emphasizing the importance of thorough freedom-to-operate assessments for stakeholders. Understanding its claims' precise language and strategic positioning is essential for corporate decision-making, whether pursuing licensing, product development, or legal enforcement.


Key Takeaways

  • JP2008546429 primarily safeguards a specific chemical synthesis method, with protection likely limited to particular process steps and conditions.
  • The patent's claims tend to be narrow, but inclusion of intermediates can broaden the scope.
  • The Japanese patent landscape is crowded with related filings, requiring thorough landscape and FTO analysis before commercialization.
  • Large pharmaceutical firms are common assignees, indicating the patent's strategic industry relevance.
  • As the patent ages, its enforceability diminishes, but it remains a critical consideration during active development phases.

FAQs

Q1: Does JP2008546429 protect the chemical compound itself or only the method?
Primarily, it protects the specific synthesis method; unless product claims are explicitly included, the compound itself may not be covered.

Q2: How can competitors design around this patent?
By altering reaction steps, using different starting materials, catalysts, or process conditions that fall outside the scope of the claims.

Q3: What is the typical expiration date of JP2008546429?
Assuming no extensions, it would expire around 2028, given a 20-year term from filing, barring patent term adjustments.

Q4: Are intermediates protected under JP2008546429?
Potentially, if the patent includes claims directed to novel intermediates used in the synthesis process.

Q5: How does the Japanese patent landscape impact global pharmaceutical innovation?
Japanese patents like JP2008546429 contribute to a dense IP environment, urging global innovators to consider filing or licensing strategies tailored to local patent landscapes.


References

[1] Japan Patent Office (JPO). Patent JP2008546429. Available via J-PlatPat.
[2] WIPO. Patent family data and related applications.
[3] Patent landscape reports and analysis on Japanese chemical process patents.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.